CAMP4 Therapeutics

CAMP4 is a biotechnology company harnessing the power of RNA to restore healthy gene expression.

CAMP4 combines a deep understanding of regulatory RNA and gene expression with a complementary and customizable oligonucleotide modality.

CAMP4 Therapeutics was founded in 2016 by Richard Young. The company is headquartered in Cambridge, Massachusetts.


CAMP4 is combining its proprietary RNA Actuating Platform (RAP) with state-of-the-art oligonucleotide technology to develop precise and programmable therapeutics that enable tunable upregulation of gene expression to treat disease.


CAMP4's RNA Actuating Platform’s proprietary insights enable them to harness the power of RNA to upregulate the expression of genes and unlock the potential to create treatments for hundreds of diseases affecting millions of patients.


CAMP4’s current pipeline is focused on diseases where oligonucleotides have proven safe and effective, including CNS and liver diseases, with the potential to expand to muscle and heart diseases.


CAMP4 is backed by AM Ventures, Northpond Ventures, Andreessen Horowitz, Polaris Partners, Enavate Sciences, Gaingels, Biogen Idec, The Kraft Group, and others. The company raised $100M in Series B round on Jul 20, 2022. This brings CAMP4's total funding to $190.6M to date.



  • Year founded: 2016
  • Funding Info: $190.6M over 4 Rounds (Latest Funding Type: Series B)
  • Yearly Revenue: NA
  • Employee Size: 51-200
  • Business Valuation: NA
  • City/Town: Cambridge
  • State: Massachusetts
  • Country: United States
Related businesses